Business Description
InflaRx is a clinical-stage pharmaceutical company based in Jena, Germany, focused on developing treatments for autoimmune and inflammatory diseases by targeting a protein called C5a, which plays a key role in driving harmful inflammation in the body. Its most advanced drug, vilobelimab, is currently in Phase 3 trials for patients with serious organ damage caused by sepsis, while two other candidates ? an oral therapy called Izicopan and an early-stage treatment called IFX002 ? are at earlier points in development. The company works with several partners, including Staidson Biopharmaceuticals, Catalent Pharma Solutions, and U.S. government health agencies, to advance its research. Founded in 2007 and formerly known as Fireman B.V., InflaRx operates across both Germany and the United States.
